Author:
Giles F J,le Coutre P D,Pinilla-Ibarz J,Larson R A,Gattermann N,Ottmann O G,Hochhaus A,Radich J P,Saglio G,Hughes T P,Martinelli G,Kim D-W,Novick S,Gillis K,Fan X,Cortes J,Baccarani M,Kantarjian H M
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference26 articles.
1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.
2. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566.
4. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.
5. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 94: 1362–1367.
Cited by
198 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献